首页>投融资

Modifi Biosciences

收并购

Modifi Biosciences is a developer of healthcare platform intended to exploit DNA defects in a wide range of cancer cells. The company's approach to fighting cancer is based on its ability to modify tumor DNA in a manner that is irreparable to cancer cells, without negatively impacting healthy cells, providing disrupting conventional oncology drug development.In October 2022, Modifi Biosciences has been selected by the National Cancer Institute for a Fast-Track Small Business Innovation Research Award of $2.4 million

https://modifibio.com/

470180

基本信息

公司全称

Modifi Biosciences
类型

临床前生物技术研发商
产业领域

药品研发/制造、医药研发/制造、化学药
公司人数

15~50人
地址

55 Church Street New Haven Connecticut; US;
联系电话
邮箱

info@modifibio.com
成立时间

2021-01-01

投融资

2024-10-25

收并购

13亿美元

MSD
2023-10-16

种子轮

430万美元

National Brain Tumor Society

Sontag Foundation

American Cancer Society BrightEdge

HighCape Capital

CT Innovations

Pathway Bioventures

Advantage Capital
2023-10-16

种子轮

430万美元

CT Innovations

Advantage Capital

National Brain Tumor Society

Sontag Foundation

American Cancer Society BrightEdge

HighCape Capital

Pathway Bioventures
2022-10-25

捐赠/众筹

240万美元

National Cancer Institute
2022-10-25

捐赠/众筹/授予

240万美元

National Cancer Institute
2022-07-28

种子轮

640万美元

Ironwood Capital

National Brain Tumor Society

HighCape Capital

CT Innovations

Yale Ventures

Brain Tumor Investment Fund
2022-07-28

种子轮

640万美元

HighCape Capital

Brain Tumor Investment Fund

National Brain Tumor Society

CT Innovations

Yale Ventures

Ironwood Capital
加载更多

Modifi Biosciences

基本信息

投融资

相关投融资企业